Liver Disease News and Research

RSS

The liver is one of the largest solid organs of the body. It is located in the upper right part of the abdomen. Most of the organ lies under cover of the rib cage.

Proteonomix receives FDA approval to commence UMK-121 Phase 1 trial in end-stage liver disease

Proteonomix, Inc., a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, today announced that the U.S. Food and Drug Administration (FDA) has granted permission to the Company to initiate a Phase 1 clinical trial with its mobilization technology UMK-121.

15 Aug 2012

Common antibiotics may risk liver injury in elderly

Regulatory warnings should be considered for the antibiotics moxifloxacin and levofloxacin because of a potential risk for liver injuries in the elderly, Canadian researchers suggest.

14 Aug 2012

Targeting elevated HLX gene expression may treat acute myeloid leukemia

Scientists at Albert Einstein College of Medicine of Yeshiva University have made a discovery involving mice and humans that could mean that people with acute myeloid leukemia (AML), a rare and usually fatal cancer, are a step closer to new treatment options. Their study results were published online today in Cancer Cell.

14 Aug 2012

WSU researchers to test novel hypothesis that cardiolipin deficiency leads to disruption of TCA cycle

Barth Syndrome (BTHS) is a rare and serious genetic disorder that primarily affects males and is passed from mother to son; women who are carriers do not show symptoms of the disorder. Fifty percent of children born to a mother who is a carrier will inherit the defective gene, and all daughters born to an affected man will be carriers. BTHS is caused by a mutation in the tafazzin gene that results in decreased production of cardiolipin, an essential lipid for energy metabolism.

8 Aug 2012

Study reports new potential NOX inhibitor therapy for liver fibrosis

A study published in the online journal Hepatology reports a potential new NADPH oxidase (NOX) inhibitor therapy for liver fibrosis, a scarring process associated with chronic liver disease that can lead to loss of liver function.

8 Aug 2012

New analysis provides overall genetic fingerprint of various Jewish subpopulations

A new genetic analysis focusing on Jews from North Africa has provided an overall genetic map of the Jewish Diasporas. The findings support the historical record of Middle Eastern Jews settling in North Africa during Classical Antiquity, proselytizing and marrying local populations, and, in the process, forming distinct populations that stayed largely intact for more than 2,000 years.

7 Aug 2012

Assumptions about liver transplant wait-list mortality challenged

The majority of liver patients who die on, or are removed from, the transplant wait-list have declined an offer of transplant, show the findings of an American study.

6 Aug 2012

TAT-ARC fusion protein helps treat acute liver failure

Acute liver failure is a life-threatening disease, characterized by a sudden, massive death of liver cells. Unfortunately, few treatment options exist, especially for advanced-stage liver failure. As a last resort a liver transplant may be the only remaining option.

3 Aug 2012

Biomimetic bioartificial livers and cell toxicity assays: an interview with Dr. Joris Braspenning, CEO Medicyte

Biomimetic bioartificial livers are liver organoids based on synthetic equivalents of the human extracellular matrix (ECM) which will be seeded with human cells.

1 Aug 2012

Obesity and heart disease risk in children: an interview with Joana Kist-van Holthe

'What defines obesity in children' is a very important question, primarily because we need to use one definition in order to be able to compare the prevalence of obesity in different countries. It is also important to have a single definition in order to evaluate whether interventions are successful or not.

31 Jul 2012

EASL calls on the UN to take action to fight against viral hepatitis infection

Marking World Hepatitis Day, the European Association for the Study of the Liver (EASL) calls on the different organizations which make up the United Nations systems to take action to fight against Viral Hepatitis (Hepatitis B and C), a potentially fatal infection of the liver which affects 500 million people.

30 Jul 2012

New drug can aid in losing weight and keeping it off

A new drug could aid in losing weight and keeping it off. The drug, described in the journal Cell Metabolism on July 26, increases sensitivity to the hormone leptin, a natural appetite suppressant found in the body. Although so far the new drug has only been tested on mice, the findings have implications for the development of new treatments for obesity in humans.

28 Jul 2012

Mylan receives FDA approval for generic Sporanox ANDA

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Itraconazole Capsules, 100 mg.

27 Jul 2012

Roundup: Ore. Gov. suggests malpractice reform; Mass. Gov. proposes new scrutiny for health care providers; Texas has offered HPV vaccine since 2007

The state can cut health care costs and reduce the number of medical-related lawsuits by requiring earlier notification of injuries as well as pretrial mediation, according to a recommendation Gov. John Kitzhaber issued Wednesday. The product of closed-door talks between representatives of interest groups including the Oregon Medical Association and the Oregon Trial Lawyers Association, Kitzhaber's recommendation now goes to a work group including lawmakers, a trial lawyer and doctor that begins public meetings next week.

27 Jul 2012

Gilead Sciences second quarter total revenues increase 13% to $2.41 billion

Gilead Sciences, Inc. announced today its results of operations for the quarter ended June 30, 2012.

26 Jul 2012

Vitamin B12 supplements and hepatitis C treatment: an interview with Gerardo Nardone and Alba Rocco

Since its discovery in 1989, hepatitis C virus (HCV) has been recognized as a major cause of chronic liver disease worldwide. The most recent WHO estimate of the prevalence of HCV infection is 2%, representing . about 150 million people. Every year, 3–4 million new people are infected with the hepatitis C virus, of those, approximately 60–80% develop chronic hepatitis, and 30% of them progress to cirrhosis and to end-stage liver disease.

26 Jul 2012

Follow-up exams for patients with celiac disease are often inadequate and highly variable

Follow-up exams for patients with celiac disease are often inadequate and highly variable, according to a new study in Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological Association (AGA).

26 Jul 2012

HIV-positive women may use new methods to help reduce frequency of cervical cancer screening

Compared to the general population, HIV-positive women have a high risk of cervical cancer and thus are advised to undergo more frequent screening tests. This creates a burden for HIV-positive patients and the health care system, leading to frequent biopsies, which often do not reveal clinically relevant disease.

23 Jul 2012

Silymarin does not offer significant improvements for patients with HCV

Silymarin, an extract of milk thistle commonly used to treat chronic liver disease by millions of people around the World, does not offer significant improvements for patients, according to a new study conducted by a nationwide group of researchers including faculty at the Perelman School of Medicine at the University of Pennsylvania.

20 Jul 2012

Bristol-Myers Squibb reports results from brivanib plus sorafenib phase III trial on HCC

Bristol-Myers Squibb Company today reported the result of the phase III BRISK-FL clinical trial of the investigational agent brivanib versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma.

20 Jul 2012

Liver Disease News and Research

Further Reading

Proteonomix receives FDA approval to commence UMK-121 Phase 1 trial in end-stage liver disease

Common antibiotics may risk liver injury in elderly

Targeting elevated HLX gene expression may treat acute myeloid leukemia

WSU researchers to test novel hypothesis that cardiolipin deficiency leads to disruption of TCA cycle

Study reports new potential NOX inhibitor therapy for liver fibrosis

New analysis provides overall genetic fingerprint of various Jewish subpopulations

Assumptions about liver transplant wait-list mortality challenged

TAT-ARC fusion protein helps treat acute liver failure

Biomimetic bioartificial livers and cell toxicity assays: an interview with Dr. Joris Braspenning, CEO Medicyte

Obesity and heart disease risk in children: an interview with Joana Kist-van Holthe

EASL calls on the UN to take action to fight against viral hepatitis infection

New drug can aid in losing weight and keeping it off

Mylan receives FDA approval for generic Sporanox ANDA

Roundup: Ore. Gov. suggests malpractice reform; Mass. Gov. proposes new scrutiny for health care providers; Texas has offered HPV vaccine since 2007

Gilead Sciences second quarter total revenues increase 13% to $2.41 billion

Vitamin B12 supplements and hepatitis C treatment: an interview with Gerardo Nardone and Alba Rocco

Follow-up exams for patients with celiac disease are often inadequate and highly variable

HIV-positive women may use new methods to help reduce frequency of cervical cancer screening

Silymarin does not offer significant improvements for patients with HCV

Bristol-Myers Squibb reports results from brivanib plus sorafenib phase III trial on HCC

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News